BACKGROUND
MYBPC3 truncating variants (MYBPC3tv) represent the most common genetic substrate in hypertrophic cardiomyopathy, yet carriers show substantial phenotypic variability despite a shared mechanism of haploinsufficiency. The contribution of additional genetic variants to this variability remains incompletely def...
S. Garcia-Hernandez, L. de la Higuera Romero, J. Larrañaga-Moreira et al.· Circulation Genomic and Prec...· 0 citations
The findings indicate that standard treatment thresholds may be insufficient, and more intensive risk-factor management is warranted in HCMG- patients, and that standard treatment thresholds may be insufficient.
P. Marin, K. Halim, P. Poveda et al.· European Heart Journal· 0 citations
Relatives with gene-elusive HCM identified through family screening exhibit a predominantly mild structural phenotype, lower arrhythmic burden, and few adverse outcomes compared with probands, which suggests a significant contribution to disease expression in this subgroup.
P. Marin, K. Halim, P. Poveda et al.· European Heart Journal· 0 citations
Screening yield is driven by uptake levels and existing family history, supporting systematic phenotypic screening even when no causative genetic variant is detected, and clinical cascade screening identifies new diagnoses in a modest but clinically meaningful proportion of relatives.
P. M. Marin, D. Tardo, K. Halim et al.· European Heart Journal· 0 citations
These findings support MVA multiparametric prediction over the traditional left ventricular ejection fraction ≤35% threshold and allow clinically meaningful arrhythmic risk classification in patients with nonischemic dilated cardiomyopathy.
Noemí Ramos-López, N. Mora-Ayestarán, Juan Pablo Ochoa et al.· Circulation· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.